JP2024540639A5 - - Google Patents

Info

Publication number
JP2024540639A5
JP2024540639A5 JP2024530470A JP2024530470A JP2024540639A5 JP 2024540639 A5 JP2024540639 A5 JP 2024540639A5 JP 2024530470 A JP2024530470 A JP 2024530470A JP 2024530470 A JP2024530470 A JP 2024530470A JP 2024540639 A5 JP2024540639 A5 JP 2024540639A5
Authority
JP
Japan
Prior art keywords
tale
effector
activator
protein according
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024530470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540639A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/082950 external-priority patent/WO2023094435A1/en
Publication of JP2024540639A publication Critical patent/JP2024540639A/ja
Publication of JP2024540639A5 publication Critical patent/JP2024540639A5/ja
Pending legal-status Critical Current

Links

JP2024530470A 2021-11-23 2022-11-23 オンターゲット/オフターゲット活性比が改善された新規taleタンパク質スキャフォールド Pending JP2024540639A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163282453P 2021-11-23 2021-11-23
US63/282,453 2021-11-23
DKPA202270104 2022-03-15
DKPA202270104 2022-03-15
PCT/EP2022/082950 WO2023094435A1 (en) 2021-11-23 2022-11-23 New tale protein scaffolds with improved on-target/off-target activity ratios

Publications (2)

Publication Number Publication Date
JP2024540639A JP2024540639A (ja) 2024-10-31
JP2024540639A5 true JP2024540639A5 (enExample) 2025-12-01

Family

ID=84487474

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024530470A Pending JP2024540639A (ja) 2021-11-23 2022-11-23 オンターゲット/オフターゲット活性比が改善された新規taleタンパク質スキャフォールド

Country Status (9)

Country Link
US (1) US20250002945A1 (enExample)
EP (1) EP4437091A1 (enExample)
JP (1) JP2024540639A (enExample)
KR (1) KR20240110844A (enExample)
AU (1) AU2022395500A1 (enExample)
CA (1) CA3238700A1 (enExample)
IL (1) IL312721A (enExample)
MX (1) MX2024006051A (enExample)
WO (1) WO2023094435A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4583890A1 (en) * 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2025181336A1 (en) 2024-03-01 2025-09-04 Cellectis Sa Compositions and methods for hbb-editing in hspc
KR20250148471A (ko) * 2024-04-02 2025-10-14 재단법인 아산사회복지재단 핵산 결합 단백질 및 SsdA를 포함하는 융합단백질 및 이의 용도
WO2026046724A1 (en) 2024-08-30 2026-03-05 Cellectis Sa Tale protein scaffolds involving fusions of monopartite and bipartite nls

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
US20140115726A1 (en) 2011-04-05 2014-04-24 Cellectis New tale-protein scaffolds and uses thereof
EP2737066B1 (en) 2011-07-29 2017-11-08 Cellectis High throughput method for assembly and cloning polynucleotides comprising highly similar polynucleotidic modules
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US10378007B2 (en) * 2012-09-03 2019-08-13 Cellectis Methods for modulating TAL specificity
CA2913872C (en) 2013-05-31 2022-01-18 Cellectis A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof

Similar Documents

Publication Publication Date Title
JP7170090B2 (ja) タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法
JP2022500017A5 (enExample)
JP2022511206A5 (enExample)
CA2710140C (en) Polypeptide libraries with a predetermined scaffold
AU2025275207A1 (en) Variants of CRISPR from Prevotella and Francisella 1 (Cpf1)
JP2022519507A5 (enExample)
AU2013344375B2 (en) Site-specific enzymes and methods of use
KR102662249B1 (ko) 후성적으로 조절되는 부위-특이적 뉴클레아제
JP2024137967A5 (enExample)
JP2021176301A (ja) 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系
US20120178647A1 (en) Engineering of zinc finger arrays by context-dependent assembly
JP2024533311A5 (enExample)
JP2024028452A5 (enExample)
JP2012522501A5 (enExample)
JP2024052886A (ja) 融合タンパク質
JP2024529425A5 (enExample)
JP2023504826A5 (enExample)
JP2004528850A (ja) 定方向進化の新規方法
WO2023109849A1 (en) Dna polymerase-mediated genome editing
MX2010011453A (es) Armazones proteinicos artificiales.
CN103764820A (zh) 序列特异性工程改造的核糖核酸酶h和用于确定dna-rna杂交物结合蛋白序列偏好的方法
CN121712899A (zh) 用于在真核细胞中准确插入dna序列的重组酶
JP2005519595A (ja) モジュラーリコンビナトリアルディスプレイライブラリー
KR102677201B1 (ko) 바이러스 뉴클레오캡시드를 이용한 결정성 단백질 기반 목적 단백질 융합 자가 조립 나노 입자 제조 플랫폼
CN112851765A (zh) 蛋白或肽与核酸共价连接的方法